A photo of Phillipe Backeljauw.

Director, Pediatric Endocrinology Fellowship Program

Director, Cincinnati Center for Pediatric and Adult Turner Syndrome Care

Clinical Director, Growth Disorders Center

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

Make an Appointment

"I believe in an honest, open and completely transparent dialogue with the patient and family."

My Biography & Research


I am a pediatric endocrinologist who specifically treats patients with growth disorders and patients with Turner syndrome. I believe in an honest, open and completely transparent dialogue with the patient and family.

During my fellowship training, which involved both patient care and research, I developed my passion for improving the diagnosis and treatment of growth disorders. My mentorship at the University of North Carolina at Chapel Hill with Dr. Judson Van Wyk and Dr. Louis Underwood, two of the “greats” in this field, convinced me that this was the area I would pursue.

I believe in a rational approach to the work-up and management of children with concerns regarding growth and physical development. I adhere to a cost-conscious approach and guide myself first by a detailed history and exam, rather than jumping to nondiscriminatory testing. I also follow a stepwise approach to solving the medical problem, knowing we may not always find a specific cause for the child’s growth problem. This is something parents should always keep in mind.

I am currently on the board of directors of the Pediatric Endocrine Society and the American Board of Pediatrics Endocrinology Subboard. My past research led to the Food and Drug Administration approval of a growth peptide to treat patients with growth hormone resistance (rhIGF-1), and I’m an international expert in the area of growth hormone resistance.

My current research seeks to find better diagnostic approaches to solving problems related to poor childhood growth. We are also evaluating newer methods for the treatment of growth disorders and how to treat novel growth disorders. In addition, I am involved in several research projects related to the comorbidities of Turner syndrome, for which we are serving the largest clinical cohort in the U.S.

I have published more than 100 peer-reviewed manuscripts, more than 100 abstracts and 17 textbook chapters. I’ve also given more than 90 invited presentations at national and international meetings.

In my free time, I love being in nature. I’m active in hiking, cycling, swimming, kayaking and golf. I also like to read nonfiction books related to philosophy and history.

Additional Languages

French, Spanish

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Endocrinology, Diabetes

Research Divisions


My Locations

My Education

MD: University of Ghent, Belgium.

Residency: Pediatric and Adolescent Medicine, Cleveland Clinic Foundation Children's Hospital, Cleveland, OH.

Fellowship: Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC.

Certification: Pediatrics, 1992; recertified, 1999, 2007; Pediatric Endocrinology, 1995; recertified, 2003, 2013.

My Publications

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. Sävendahl, L; Polak, M; Backeljauw, P; Blair, JC; Miller, BS; Rohrer, TR; Hokken-Koelega, A; Pietropoli, A; Kelepouris, N; Ross, J. Journal of Clinical Endocrinology and Metabolism. 2021; 106:1728-1741.

Impact of short stature on quality of life: A systematic literature review. Backeljauw, P; Cappa, M; Kiess, W; Law, L; Cookson, C; Sert, C; Whalen, J; Dattani, MT. Growth Hormone and IGF Research. 2021; 57-58.

PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort. Backeljauw, P; Miller, BS; Levy, R; McCormick, K; Zouater, H; Zabransky, M; Campbell, K. Journal of Pediatric Endocrinology and Metabolism. 2021; 34:431-440.

The continuum between GH deficiency and GH insensitivity in children. Savage, MO; Storr, HL; Backeljauw, PF. Reviews in Endocrine and Metabolic Disorders. 2021; 22:91-99.

Progression of Vasculopathy in Young Individuals with Turner Syndrome. Blunden, CE; Urbina, EM; Lawson, SA; Gutmark-Little, I; Shah, AS; Khoury, PR; Backeljauw, PF. Pediatric Cardiology. 2021; 42:481-491.

Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome. Rohrer, TR; Abuzzahab, J; Backeljauw, P; Birkegård, AC; Blair, J; Dahlgren, J; Júlíusson, PB; Ostrow, V; Pietropoli, A; Polak, M; et al. Hormone Research in Paediatrics. 2021; 93:380-395.

Influence of Material Model and Aortic Root Motion in Finite Element Analysis of Two Exemplary Cases of Proximal Aortic Dissection. Subramaniam, DR; Gutmark, E; Andersen, N; Nielsen, D; Mortensen, K; Gravholt, C; Backeljauw, P; Gutmark-Little, I. Journal of Biomechanical Engineering. 2021; 143.

Developmental Adaptive Immune Defects Associated with STAT5B Deficiency in Three Young Siblings. Foley, CL; Al Remeithi, SS; Towe, CT; Dauber, A; Backeljauw, PF; Tyzinski, L; Kumar, AR; Hwa, V. Journal of Clinical Immunology. 2021; 41:136-146.

Clinical characteristics and rate of dilatation in Turner syndrome patients treated for aortic dilatation. Pater, CM; Gutmark-Little, I; Tretter, JT; Martin, LJ; Backeljauw, P; Brown, NM. American Journal of Medical Genetics, Part A. 2021; 185:141-149.

17 Turner Syndrome. Backeljauw, P; Chernausek, SD; Gravholt, CH; Kruszka, P. Sperling Pediatric Endocrinology. 2021.